The prognostic and predictive values of circulating HER-2/neu extracellular domain in patients with metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 114, Issue 3, 2009, Pages 513-515

  Abu Khalaf, Maysa M ^a   Harris, Lyndsay ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BREAST CANCER; CANCER SURVIVAL; DISEASE ASSOCIATION; HUMAN; METASTASIS; NOTE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 61449122107     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0145-8     Document Type: Note

References (17)

1. DJ Slamon GM Clark SG Wong 1987 Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 177 182 10.1126/science.3798106
2. DJ Slamon W Godolphin LA Jones 1989 Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 707 712 10.1126/science.2470152
3. EH Romond EA Perez J Bryant 2005 Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 1673 1684 10.1056/NEJMoa052122
4. MJ Piccart-Gebhart M Procter B Leyland-Jones 2005 Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 1659 1672 10.1056/NEJMoa052306
5. T Yamamoto S Ikawa T Akiyama 1986 Similarity of protein encoded by the human c-erbB-2 gene to epidermal growth factor receptor Nature 319 230 234 10.1038/319230a0
6. SA Rosenberg 1996 The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens Annu Rev Med 47 481 491 10.1146/annurev.med.47.1.481
7. WP Carney R Neumann A Lipton 2004 Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer Clin Breast Cancer 5 2 105 116
8. WP Carney R Neumann A Lipton 2003 Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer Clin Chem 49 10 1579 1598 10.1373/49.10.1579
9. A Lipton SM Ali K Leitzel 2002 Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer J Clin Oncol 20 1467 1472 10.1200/JCO.20.6.1467
10. A Lipton SM Ali K Leitzel L Demers HA Harvey HA Chaudri-Ross 2003 Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen J Clin Oncol 21 1967 1972 10.1200/JCO.2003.09.098
11. D Hayes H Yamauchi G Broadwater 2001 Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662 Clin Cancer Res 7 601 604
12. FJ Esteva V Valero D Booser LT Guerra JL Murray L Pusztai 2002 Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer J Clin Oncol 20 1800 1808 10.1200/JCO.2002.07.058
13. AM Dnistrian MK Schwartz DC Schwartz 2002 Significance of serum her-2/neu oncoprotein, CA 15-3, and CEA in the clinical evaluation of metastatic breast cancer J Clin Ligand Assay 25 215 220
14. WJ Kostler B Schwab CF Singer 2004 Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer Clin Cancer Res 10 1618 1624 10.1158/1078-0432.CCR-0385-3
15. HJ Burstein LN Harris PK Marcom 2003 Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm J Clin Oncol 21 2889 2895 10.1200/JCO.2003.02.018
16. Esteva F, Cheli C, Fritsche H et al (2005) Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies. Breast Cancer Res 7(4):R436-R443
17. Ali S, Carney W, Esteva F, Fornier M, Harris L et al (2008) Human epidermal growth factor 2 proto-oncogene and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer. Cancer (accepted June 2008)